Molecular mechanism of circRNAs in drug resistance in renal cell carcinoma-Reference-Cited by-同舟云学术

Molecular mechanism of circRNAs in drug resistance in renal cell carcinoma

Published:2022-11-24 Issue:1 Volume:22 Page:
ISSN:1475-2867
Container-title:Cancer Cell International
language:en
Short-container-title:Cancer Cell Int

Author:

Qin Shuang,Wang Yuting,Wang Peijun,Lv Qi

Abstract

AbstractRenal cell carcinoma (RCC) is one of the most common malignant tumors with a poor response to radiotherapy and chemotherapy. The advent of molecular targeted drugs has initiated great breakthroughs in the treatment of RCC. However, drug resistance to targeted drugs has become an urgent problem. Various studies across the decades have confirmed the involvement of circular RNAs (circRNAs) in multiple pathophysiological processes and its abnormal expression in many malignant tumors. This review speculated that circRNAs can provide a new solution to drug resistance in RCC and perhaps be used as essential markers for the early diagnosis and prognosis of RCC. Through the analysis and discussion of relevant recent research, this review explored the relationship of circRNAs to and their regulatory mechanisms in drug resistance in RCC. The results indicate an association between the expression of circRNAs and the development of RCC, as well as the involvement of circRNAs in drug resistance in RCC.

Funder

Shanghai 2022 "Science and Technology Innovation Action Plan" Natural Science Fund project application guide

Shanghai 2022 "Science and Technology Innovation Action Plan" experimental animal Research project application Guide/animal model research, development and application

Fundamental Research Funds for central Universities of Tongji University

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

https://link.springer.com/content/pdf/10.1186/s12935-022-02790-w.pdf

Reference72 articles.

1. Hyuna Sung, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. Cancer J Clini. 2021;71(3):209–49.

2. Ochocki JD, et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity[J]. Cell Metab. 2018;27(6):1263-1280.e6.

3. Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol. 2016;69(1):4–6. https://doi.org/10.1016/j.eururo.2015.10.017 (Epub 2015 Oct 24 PMID: 26508312).

4. Chen B, Wang M, Huang R, Liao K, Wang T, Yang R, Zhang W, Shi Z, Ren L, Lv Q, Ma C, Lin Y, Qiu Y. Circular RNA circLGMN facilitates glioblastoma progression by targeting miR-127-3p/LGMN axis. Cancer Lett. 2021;1(522):225–37. https://doi.org/10.1016/j.canlet.2021.09.030 (Epub 2021 Sep 25 PMID: 34582975).